Literature DB >> 20363749

The angiogenic inhibitor long pentraxin PTX3 forms an asymmetric octamer with two binding sites for FGF2.

Antonio Inforzato1, Clair Baldock, Thomas A Jowitt, David F Holmes, Ragnar Lindstedt, Marcella Marcellini, Vincenzo Rivieccio, David C Briggs, Karl E Kadler, Antonio Verdoliva, Barbara Bottazzi, Alberto Mantovani, Giovanni Salvatori, Anthony J Day.   

Abstract

The inflammation-associated long pentraxin PTX3 plays key roles in innate immunity, female fertility, and vascular biology (e.g. it inhibits FGF2 (fibroblast growth factor 2)-mediated angiogenesis). PTX3 is composed of multiple protomers, each composed of distinct N- and C-terminal domains; however, it is not known how these are organized or contribute to its functional properties. Here, biophysical analyses reveal that PTX3 is composed of eight identical protomers, associated through disulfide bonds, forming an elongated and asymmetric, molecule with two differently sized domains interconnected by a stalk. The N-terminal region of the protomer provides the main structural determinant underlying this quaternary organization, supporting formation of a disulfide-linked tetramer and a dimer of dimers (a non-covalent tetramer), giving rise to the asymmetry of the molecule. Furthermore, the PTX3 octamer is shown to contain two FGF2 binding sites, where it is the tetramers that act as the functional units in ligand recognition. Thus, these studies provide a unifying model of the PTX3 oligomer, explaining both its quaternary organization and how this is required for its antiangiogenic function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20363749      PMCID: PMC2878532          DOI: 10.1074/jbc.M109.085639

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  50 in total

1.  C-reactive protein and SAP-like pentraxin are both present in Limulus polyphemus haemolymph: crystal structure of Limulus SAP.

Authors:  A K Shrive; A M Metcalfe; J R Cartwright; T J Greenhough
Journal:  J Mol Biol       Date:  1999-07-30       Impact factor: 5.469

Review 2.  The long pentraxin PTX3 in vascular pathology.

Authors:  Alberto Mantovani; Cecilia Garlanda; Barbara Bottazzi; Giuseppe Peri; Andrea Doni; Yeny Martinez de la Torre; Roberto Latini
Journal:  Vascul Pharmacol       Date:  2006-08-23       Impact factor: 5.773

3.  Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo.

Authors:  Maura Camozzi; Serena Zacchigna; Marco Rusnati; Daniela Coltrini; Genaro Ramirez-Correa; Barbara Bottazzi; Alberto Mantovani; Mauro Giacca; Marco Presta
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-07-14       Impact factor: 8.311

4.  PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation.

Authors:  F Fazzini; G Peri; A Doni; G Dell'Antonio; E Dal Cin; E Bozzolo; F D'Auria; L Praderio; G Ciboddo; M G Sabbadini; A A Manfredi; A Mantovani; P R Querini
Journal:  Arthritis Rheum       Date:  2001-12

5.  Investigating interactions of the pentraxins serum amyloid P component and C-reactive protein by mass spectrometry.

Authors:  J Andrew Aquilina; Carol V Robinson
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

6.  Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition.

Authors:  Ying Jie Ma; Andrea Doni; Tina Hummelshøj; Christian Honoré; Antonio Bastone; Alberto Mantovani; Nicole M Thielens; Peter Garred
Journal:  J Biol Chem       Date:  2009-07-24       Impact factor: 5.157

7.  Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure.

Authors:  Satoshi Suzuki; Yasuchika Takeishi; Takeshi Niizeki; Yo Koyama; Tatsuro Kitahara; Toshiki Sasaki; Mina Sagara; Isao Kubota
Journal:  Am Heart J       Date:  2007-09-27       Impact factor: 4.749

8.  Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis.

Authors:  Marco Rusnati; Maura Camozzi; Emanuela Moroni; Barbara Bottazzi; Giuseppe Peri; Stefano Indraccolo; Alberto Amadori; Alberto Mantovani; Marco Presta
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

9.  Structural basis for complement factor H linked age-related macular degeneration.

Authors:  Beverly E Prosser; Steven Johnson; Pietro Roversi; Andrew P Herbert; Bärbel S Blaum; Jess Tyrrell; Thomas A Jowitt; Simon J Clark; Edward Tarelli; Dusan Uhrín; Paul N Barlow; Robert B Sim; Anthony J Day; Susan M Lea
Journal:  J Exp Med       Date:  2007-09-24       Impact factor: 14.307

10.  Negative Staining and Image Classification - Powerful Tools in Modern Electron Microscopy.

Authors:  Melanie Ohi; Ying Li; Yifan Cheng; Thomas Walz
Journal:  Biol Proced Online       Date:  2004-03-19       Impact factor: 3.244

View more
  55 in total

1.  Associations of pentraxin-3 with cardiovascular events, incident heart failure, and mortality among persons with coronary heart disease: data from the Heart and Soul Study.

Authors:  Ruth Dubin; Yongmei Li; Joachim H Ix; Michael G Shlipak; Mary Whooley; Carmen A Peralta
Journal:  Am Heart J       Date:  2012-02       Impact factor: 4.749

2.  Constitutive expression of pentraxin 3 (PTX3) protein by human amniotic membrane cells leads to formation of the heavy chain (HC)-hyaluronan (HA)-PTX3 complex.

Authors:  Suzhen Zhang; Ying-Ting Zhu; Szu-Yu Chen; Hua He; Scheffer C G Tseng
Journal:  J Biol Chem       Date:  2014-03-20       Impact factor: 5.157

3.  Expression of recombinant human complement C1q allows identification of the C1r/C1s-binding sites.

Authors:  Isabelle Bally; Sarah Ancelet; Christine Moriscot; Florence Gonnet; Alberto Mantovani; Régis Daniel; Guy Schoehn; Gérard J Arlaud; Nicole M Thielens
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-06       Impact factor: 11.205

4.  Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.

Authors:  Xiuhui Chen; Lingegowda S Mangala; Linda Mooberry; Emine Bayraktar; Santosh K Dasari; Shaolin Ma; Cristina Ivan; Karem A Court; Cristian Rodriguez-Aguayo; Recep Bayraktar; Sangram Raut; Nirupama Sabnis; Xianchao Kong; Xianbin Yang; Gabriel Lopez-Berestein; Andras G Lacko; Anil K Sood
Journal:  Oncogene       Date:  2019-07-09       Impact factor: 9.867

5.  miR-93/106b and their host gene, MCM7, are differentially expressed in leiomyomas and functionally target F3 and IL-8.

Authors:  Tsai-Der Chuang; Xiaoping Luo; Harekrushna Panda; Nasser Chegini
Journal:  Mol Endocrinol       Date:  2012-05-03

6.  Interferon-α coincides with suppressed levels of pentraxin-3 (PTX3) in systemic lupus erythematosus and regulates leucocyte PTX3 in vitro.

Authors:  L Wirestam; H Enocsson; T Skogh; M L Eloranta; L Rönnblom; C Sjöwall; J Wetterö
Journal:  Clin Exp Immunol       Date:  2017-03-31       Impact factor: 4.330

7.  Immobilized heavy chain-hyaluronic acid polarizes lipopolysaccharide-activated macrophages toward M2 phenotype.

Authors:  Hua He; Suzhen Zhang; Sean Tighe; Ji Son; Scheffer C G Tseng
Journal:  J Biol Chem       Date:  2013-07-22       Impact factor: 5.157

8.  PTX3, a Humoral Pattern Recognition Molecule, in Innate Immunity, Tissue Repair, and Cancer.

Authors:  Cecilia Garlanda; Barbara Bottazzi; Elena Magrini; Antonio Inforzato; Alberto Mantovani
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 9.  The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling.

Authors:  Barbara Bottazzi; Antonio Inforzato; Massimo Messa; Marialuisa Barbagallo; Elena Magrini; Cecilia Garlanda; Alberto Mantovani
Journal:  J Hepatol       Date:  2016-02-26       Impact factor: 25.083

Review 10.  Pentraxins in the activation and regulation of innate immunity.

Authors:  Kenji Daigo; Antonio Inforzato; Isabella Barajon; Cecilia Garlanda; Barbara Bottazzi; Seppo Meri; Alberto Mantovani
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.